SEOM clinical guideline for the management of cutaneous melanoma (2020)

Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and...

ver descrição completa

Detalhes bibliográficos
Autores: Majem Tarruella, Margarita|||0000-0002-9919-7485, Manzano, J. L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E., de La Cruz-Merino, Luis|||0000-0002-5333-0535, Espinosa, E., González-Cao, María|||0000-0003-3791-540X, Berrocal, Alfonso
Formato: artículo
Fecha de publicación:2021
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:269846
Acesso em linha:https://ddd.uab.cat/record/269846
https://dx.doi.org/urn:doi:10.1007/s12094-020-02539-9
Access Level:acceso abierto
Palavra-chave:Melanoma
Adjuvant treatment metastatic treatment
Staging
id ES_10ccaa27fadfd1c9d5c811f9cd9745eb
oai_identifier_str oai:ddd.uab.cat:269846
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM clinical guideline for the management of cutaneous melanoma (2020)Majem Tarruella, Margarita|||0000-0002-9919-7485Manzano, J. L.Marquez-Rodas, I.Mujika, K.Muñoz-Couselo, E.Pérez-Ruiz, E.de La Cruz-Merino, Luis|||0000-0002-5333-0535Espinosa, E.González-Cao, María|||0000-0003-3791-540XBerrocal, AlfonsoMelanomaAdjuvant treatment metastatic treatmentStagingMelanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/269846https://dx.doi.org/urn:doi:10.1007/s12094-020-02539-9reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2698462026-06-06T12:50:31Z
dc.title.none.fl_str_mv SEOM clinical guideline for the management of cutaneous melanoma (2020)
title SEOM clinical guideline for the management of cutaneous melanoma (2020)
spellingShingle SEOM clinical guideline for the management of cutaneous melanoma (2020)
Majem Tarruella, Margarita|||0000-0002-9919-7485
Melanoma
Adjuvant treatment metastatic treatment
Staging
title_short SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_full SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_fullStr SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_full_unstemmed SEOM clinical guideline for the management of cutaneous melanoma (2020)
title_sort SEOM clinical guideline for the management of cutaneous melanoma (2020)
dc.creator.none.fl_str_mv Majem Tarruella, Margarita|||0000-0002-9919-7485
Manzano, J. L.
Marquez-Rodas, I.
Mujika, K.
Muñoz-Couselo, E.
Pérez-Ruiz, E.
de La Cruz-Merino, Luis|||0000-0002-5333-0535
Espinosa, E.
González-Cao, María|||0000-0003-3791-540X
Berrocal, Alfonso
author Majem Tarruella, Margarita|||0000-0002-9919-7485
author_facet Majem Tarruella, Margarita|||0000-0002-9919-7485
Manzano, J. L.
Marquez-Rodas, I.
Mujika, K.
Muñoz-Couselo, E.
Pérez-Ruiz, E.
de La Cruz-Merino, Luis|||0000-0002-5333-0535
Espinosa, E.
González-Cao, María|||0000-0003-3791-540X
Berrocal, Alfonso
author_role author
author2 Manzano, J. L.
Marquez-Rodas, I.
Mujika, K.
Muñoz-Couselo, E.
Pérez-Ruiz, E.
de La Cruz-Merino, Luis|||0000-0002-5333-0535
Espinosa, E.
González-Cao, María|||0000-0003-3791-540X
Berrocal, Alfonso
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Melanoma
Adjuvant treatment metastatic treatment
Staging
topic Melanoma
Adjuvant treatment metastatic treatment
Staging
description Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/269846
https://dx.doi.org/urn:doi:10.1007/s12094-020-02539-9
url https://ddd.uab.cat/record/269846
https://dx.doi.org/urn:doi:10.1007/s12094-020-02539-9
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403530023927808
score 15.300719

Registos relacionados